SCHEMBL2402064

SCHEMBL2402064

CC(NC(=O)C1=NOC2(CCN(S(=O)(=O)c3ccc(F)cc3)CC2)C1)C(=O)Nc1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
KMT2A Q03164 6/20 0.49
ALDH1A1 P00352 5/20 0.49
LMNA P02545 5/20 0.45
HTT P42858 4/20 0.45
MEN1 O00255 4/20 0.45
GAA P10253 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX12 P18054 1/20 0.45
PKM P14618 2/20 0.43
PABPC1 P11940 1/20 0.42
APOBEC3A P31941 1/20 0.42
EIF4H Q15056 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
STAT1 P42224 1/20 0.41
HPGD P15428 1/20 0.41
USP2 O75604 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
GPR183 P32249 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433020 0.87 KMT2A (0.49) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL2400043 0.85 USP2 (0.42) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL2402252 0.79 LIPE (0.47) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL2399280 0.74 GPR183 (0.42) KMT2AALDH1A1MEN1PKMGPR183
SCHEMBL6409630 0.73 ALDH1A1 (0.48) KMT2AALDH1A1LMNAHTTMEN1
SCHEMBL6431599 0.73 USP2 (0.39) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL2401315 0.72 NAMPT (0.52) KMT2AALDH1A1LMNAMEN1GAA
SCHEMBL2580532 0.71 LMNA (0.43) KMT2AALDH1A1LMNAMEN1GAA
SCHEMBL2402390 0.71 MAPT (0.58) MAPTKMT2AALDH1A1LMNAMEN1
SCHEMBL2400977 0.71 ALDH1A1 (0.48) KMT2AALDH1A1LMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 MAPT 3594/4885KMT2A 3636/4885ALDH1A1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.